论文部分内容阅读
目的观察脑出血应用颅内血肿微创清除术联合鼠神经生长因子(苏肽生)治疗的临床疗效。方法随机选取94例河南省人民医院2013年8月—2014年8月诊治的脑出血患者,随机分组。对照组予以内科保守治疗,研究组47例予以颅内血肿微创清除术联合鼠神经生长因子(苏肽生)治疗,对比分析两组患者治疗前后的神经功能缺损程度评分(NIHSS)、疼痛(VAS)评分、生活质量量表(ADL)及术后并发症发生情况。结果研究组NIHSS评分及VAS评分均小于对照组,差异有统计学意义(P<0.05);研究组患者术后并发症发生率低于对照组,两组对比差异较为明显(P<0.05);研究组术后ADL评分(83.4±11.3)分与对照组(72.6±8.9)相比,明显较高,差异有统计学意义(P<0.05)。结论脑出血应用颅内血肿微创清除术联合鼠神经生长因子(苏肽生)治疗疗效显著,能有效改善患者神经功能和疼痛程度,提高患者术后生活质量,且术后并发症少,值得推广。
Objective To observe the clinical curative effect of minimally invasive intracranial hematoma removal combined with nerve growth factor (Su peptide) in patients with intracerebral hemorrhage. Methods 94 cases of ICH patients treated by Henan Provincial People’s Hospital from August 2013 to August 2014 were randomly divided into two groups. In the control group, 47 patients were treated with minimally invasive intracranial hematoma combined with mouse nerve growth factor (SU), and the NIHSS and pain scores were compared between the two groups before and after treatment VAS score, quality of life scale (ADL) and postoperative complications. Results The scores of NIHSS and VAS in study group were lower than those in control group (P <0.05). The incidence of postoperative complications in study group was lower than that in control group (P <0.05). The postoperative ADL score (83.4 ± 11.3) in the study group was significantly higher than that in the control group (72.6 ± 8.9), with significant difference (P <0.05). Conclusions The treatment of intracerebral hemorrhage with intracranial hematoma minimally invasive surgery combined with mouse nerve growth factor (Su peptide) has significant curative effect, which can effectively improve the neurological function and pain degree, improve postoperative quality of life, and less postoperative complications, which is worth Promotion.